pylori associated dyspepsia ( To facilitate the management of FD, the Rome Consensus subdivided FD into two subtypes: Postprandial Distress Syndrome (PDS) (60%) characterized by meal-related symptoms, such as postprandial fullness, early satiation, postprandial epigastric pain and other symptoms triggered by food ingestion, and Epigastric Pain Syndrome (EPS) (20%) characterized by epigastric pain and burning ( FD is extremely common, with estimates of 1030% prevalence in the general population, and is associated with substantial medical care costs and a considerable health economic impact ( Finally, FD patients also show an important degree of overlap with gastro-esophageal reflux disease (GERD) ( Gastroparesis Gastroparesis is characterized by delayed gastric emptying and by upper gastrointestinal symptoms (nausea, vomiting, abdominal pain, early satiety, bloating) in the absence of mechanical obstruction ( Gastrointestinal Peptides In the classical pathophysiological model, functional gastrointestinal disorders (FGIDs) are considered heterogeneous conditions, and symptoms are attributed to a combination of motility disturbances, visceral hypersensitivity, low grade mucosal immune activation, and altered processing of gut-brain signals ( Recent research has focused on visceral hypersensitivity as a common mechanism determining symptom severity and impact across several functional gastrointestinal disorders ( The gastrointestinal mucosa expresses a wide range of chemosensing receptors, which detect the presence and nature of nutrients in the lumen ( There is recent evidence of nutrient-specific enhanced release of gut peptide hormones [motilin, ghrelin, peptide YY (PYY), cholecystokinin (CCK), and glucagon-like peptide 1 (GLP-1)] in FD, which was correlated to intensities of the provoked symptoms
Among them, both -casein and -casein have two cysteines and have been reported to play an important role in the formation of cross-links (Fox et al
(PubMed) Ferrigno L, Aldigeri R, Rosmini F, Sperduto RD, Maraini G, Italian-American Cataract Study G
Some users may experience mild side effects, such as redness or irritation at the injection site, which typically subsides on its own
doi:10.1590/0004-282x-anp-2021-0192 Visser EJ, Drummond PD, Lee-Visser JLA
Glucagon-like peptide-1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, have transformed obesity management, producing weight loss that narrows the gap with metabolic surgery at the same time as reducing the risk of obesity-related complications [2]
